QPW
CRSP icon

Quantum Private Wealth’s CRISPR Therapeutics CRSP Stock Holding History

Quantum Private Wealth’s Portfolio CRSP Stock Details CRSP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$316K Sell
5,800
-500
-8% -$26.4K 0.08% 131
2026
Q1 		$300K Buy
6,300
+1,400
+29% +$73.8K 0.09% 124
2025
Q4 		$257K Buy
+4,900
New +$293K 0.08% 141

Other funds holding CRSP

AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
OAG
Orbis Allan Gray Hamilton, Bermuda $29.1B AUM 60.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
SOCM
SR One Capital Management Wayne, Pennsylvania $1.04B AUM 262.99% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Quantum Private Wealth's CRSP Position: Q2 2026 in Review

Quantum Private Wealth reduced its CRISPR Therapeutics (CRSP) stake by 7.9% in Q2 2026, selling an estimated $26.4K and leaving 5,800 shares worth $316K. The position accounts for 0.08% of the portfolio, ranked #131.

Quantum Private Wealth first reported a position in CRSP in Q4 2025 and has held it in 3 quarters since. 523 funds tracked by Wall St. Rank hold CRSP as of Q2 2026.

  • Quantum Private Wealth held 5,800 shares of CRISPR Therapeutics worth $316K as of Q2 2026.
  • Quantum Private Wealth sold 500 CRISPR Therapeutics shares in Q2 2026, an estimated $26.4K.
  • CRISPR Therapeutics made up 0.08% of Quantum Private Wealth's portfolio in Q2 2026, its #131 holding.
  • Quantum Private Wealth first reported a position in CRISPR Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 523 funds tracked by Wall St. Rank held CRISPR Therapeutics as of Q2 2026.

Based on Quantum Private Wealth's 13F filing for Q2 2026, filed 29 Jul 2026.